GMP Standard Ingredient Rivastigmine Tartrate / Galanthamine Hydrobromide CAS 1953-04-4
Quick detail
Galantamine Hydrobromide
Galantamine Hydrobromide CAS: 1953-04-4
Galantamine Hydrobromide MF: C17H22BrNO3
Galantamine Hydrobromide MW: 368.27
Galantamine Hydrobromide EINECS: 217-780-5
Product Categories: Alkaloids;Alkaloids (Others);Biochemistry;Functional Products;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API's;Acetylcholine receptor;API;Chiral Reagents;Reminyl;Other APIs;Pharmaceutical intermediates
MP 256 °C
Storage temp. −20°C
Chemical Properties White to Off-White Powder
Usage A selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism.
Usage Alzheimer treatment;Cholinesterase inhibitor
Usage anticholinesterase, analgesic, antiAlzheimer
Rivastigmine Tartrate / Galanthamine Hydrobromide Drug Interactions:
(1) Rivastigmine is mainly through hydrolysis cholinesterase metabolism, cytochrome P450 isozymes are rarely involved in its metabolism. Therefore, the product and by other drugs metabolized by these enzymes does not exist pharmacokinetic interactions.
(2) study in healthy volunteers found the product (a single dose of 3mg) with digoxin, warfarin, diazepam or fluoxetine, have no pharmacokinetic interactions. Warfarin induced by prothrombin time extension are not affected by this product. After combination of digoxin and the product found no adverse impact on cardiac conduction.
(3) In clinical studies of patients with Alzheimer's disease (AD), the goods and some commonly used prescription drugs combined, such as antacids, antiemetics, hypoglycemic agents, β-blockers, calcium channel blockers agents, inotropic agents, anti-angina drugs, non-steroidal anti-inflammatory drugs, estrogens, analgesics, tranquilizers, antihistamines, etc., and risk of clinically relevant adverse reaction does not increase
(4) In view of the pharmacokinetic effect of this product, this product should not be used in combination with other cholinergic drugs, it may interfere with the activity of anticholinergic drugs.
(5) There is no experience of this product with anti Parkinson drugs, anti anxiety drugs (except for stability), antipsychotic drugs, antiepileptic drugs, antidepressant drugs.
(6) rivastigmine tartrate as a cholinesterase inhibitor, during anesthesia, it can be used to enhance succinylcholine-type muscle relaxant effect.
Rivastigmine Tartrate / Galanthamine Hydrobromide Application:
For the treatment of mild to moderate Alzheimer's disease symptoms of dementia.
Pathological changes in Alzheimer's disease mainly involve the cholinergic nerve pathways from the basal forebrain to the cerebral cortex and hippocampus. These pathways are known to be related to attention, learning ability, memory, and other cognitive processes.
Carbamate tartrate is a carbamate-selective acetylcholinesterase inhibitor that promotes cholinergic nerve conduction by delaying the function of complete cholinergic neurons to release the release of acetylcholine. The results of animal experiments showed that valacridine tartrate could selectively enhance the effect of acetylcholine in cerebral cortex and hippocampus.
Therefore, Aisi can improve Alzheimer's disease in patients with cholinergic-mediated cognitive dysfunction. In addition, cholinesterase inhibitors can slow the formation of amyloid b-amyloid precursor protein (APP) fragments. Amyloid plaque is Alzheimer's disease tartaric acid rivastigmine by the target enzyme into a covalent complex and the latter temporarily lost activity.
The activity of acetylcholinesterase in cerebrospinal fluid (CSF) decreased by nearly 40% within 1.5 hours after 3 mg of human administration. After the drug reaches its maximum inhibitory effect, the enzyme activity is restored to the basal level for approximately 9 hours. The inhibition of acetylcholinesterase in ruthenate tartrate in patients with Alzheimer's disease was dose-dependent, with a maximum test dose of 6 mg twice daily.
Rivastigmine Tartrate / Galanthamine Hydrobromide COA
Items |
Specification |
Appearance |
Brown to Brown yellow powder(Relate to Purity) |
Oder |
Characteristic |
Taste |
Characteristic |
Paiticle size |
Pass 80 mesh |
Loss on drying |
≤5% |
Heavy metals |
<10ppm |
As |
<1ppm |
Pb |
<3ppm |
Assay |
Result |
Evodiamine |
≥10% |
Total Plate Count |
<10000cfu/g or <1000cfu/g(Irradiation) |
Yeast & Mold |
<300cfu/g or 100cfu/g(Irradiation) |
E.Coli |
Negative |
Salmonella |
Negative |